Daily Stock Analysis, HCM, Hutchison China MediTech Ltd, priceseries

Hutchison China MediTech Ltd. Daily Stock Analysis
Stock Information
Open
30.60
Close
30.35
High
30.60
Low
29.80
Previous Close
30.51
Daily Price Gain
-0.16
YTD High
32.55
YTD High Date
Apr 10, 2019
YTD Low
20.83
YTD Low Date
Jan 8, 2019
YTD Price Change
7.55
YTD Gain
33.11%
52 Week High
39.68
52 Week High Date
Nov 14, 2018
52 Week Low
20.83
52 Week Low Date
Jan 8, 2019
52 Week Price Change
-2.58
52 Week Gain
-7.83%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 13. 2017
15.97
Apr 4. 2017
19.51
16 Trading Days
22.16%
Link
LONG
Jun 13. 2017
21.09
Jun 27. 2017
22.97
10 Trading Days
8.90%
Link
LONG
Aug 2. 2017
23.29
Aug 11. 2017
24.73
7 Trading Days
6.20%
Link
LONG
Sep 26. 2017
26.60
Oct 17. 2017
29.91
15 Trading Days
12.46%
Link
LONG
Nov 13. 2017
30.54
Nov 28. 2017
33.77
10 Trading Days
10.57%
Link
LONG
Dec 21. 2017
33.96
Jan 10. 2018
38.47
12 Trading Days
13.28%
Link
LONG
Jul 11. 2018
30.95
Jul 30. 2018
32.81
13 Trading Days
6.01%
Link
LONG
Sep 25. 2018
28.88
Oct 5. 2018
30.58
8 Trading Days
5.90%
Link
LONG
Feb 11. 2019
22.95
Mar 7. 2019
26.41
17 Trading Days
15.08%
Link
Company Information
Stock Symbol
HCM
Exchange
NasdaqGS
Company URL
http://www.chi-med.com
Company Phone
852-2121-3888
CEO
Christian Hogg
Headquarters
-
Business Address
22ND FLOOR HUTCHISON HOUSE, 10 HARCOURT ROAD, HONG KONG, HONG KONG 00000
Sector
Equity
Industry Category
-
Industry Group
-
CIK
0001648257
About

Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the following business segments: China Healthcare, Drug Research and Development, and Consumer Products. The China Healthcare segment engages in the development, manufacture, distribution and selling of over-the-counter products, prescription products and health supplements products. The Drug Research & Development segment develops botanical and small molecule drugs for the global market and focuses on the oncology and immunology therapeutic areas. It also provides mainly to drug discoveries and other pharmaceutical research and development activities, and the provision of research and development services. The Consumer Products segment engages in the selling of health oriented consumer products. The company was founded in June 2000 and is headquartered in Hong Kong.

Description

Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health-related consumer products primarily in the People's Republic of China. It operates through Innovation Platform and Commercial Platform segments. The company provides drug research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and health-related consumer products under the Bai Yun Shan and Shang Yao brands. It also develops clinical drug candidates, including AZD6094 that is in Phase Ib clinical trial for treating non-small cell lung and gastric cancer; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib, a Phase Ib clinical trial product for neuroendocrine tumors and thyroid cancers; and HMPL-523, a preclinical stage product for the treatment of immunology, rheumatoid arthritis, lupus, and hematological cancers. In addition, the company is developing Epitinib for the treatment of non-small cell lung cancer; Theliatinib, a Phase I clinical trial product for the treatment of solid tumors; HMPL-689, a preclinical stage product for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-004 that is in Phase III clinical trials for ulcerative colitis and Crohn's disease; and HMPL-453 that is in preclinical stage for the treatment of solid tumors. Hutchison China MediTech Limited has strategic collaborations with multinational pharmaceutical and healthcare companies, including AstraZeneca AB (Publ); Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Nestlé Health Science SA. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.